SCHEDULE 13G/A: BlackRock, Inc. Discloses 15.3% Passive Stake in Omnicell, Inc.

BlackRock, Inc. has filed an Amendment No. 18 to Schedule 13G, reporting a beneficial ownership of 15.3% in Omnicell, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 7,149,987 shares of Omnicell, Inc. common stock.
• This stake represents 15.3% of the total outstanding common stock of Omnicell, Inc.
• BlackRock holds sole voting power over 7,060,803 shares and sole dispositive power over 7,149,987 shares.
• The filing is an Amendment No. 18 to Schedule 13G, indicating an update to a previously reported ownership position.
• BlackRock certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Omnicell, Inc.
• One of BlackRock's entities, iShares Core S&P Small-Cap ETF, is identified as having an interest of more than five percent of Omnicell, Inc.'s total outstanding common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable passive investment by a major institutional investor, which is generally a positive signal of confidence in the company. However, it provides no operational or financial performance details of Omnicell itself.

Positives

• BlackRock, a prominent institutional investor, maintains a substantial 15.3% stake in Omnicell, Inc., which can be interpreted as a vote of confidence in the company's long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, suggesting a stable, passive investment rather than an activist stance.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Omnicell's operational or financial performance, nor does it indicate any future investment intentions by BlackRock beyond its stated passive investment strategy.

Management Comments

• BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing represents a routine disclosure by a major global asset manager, BlackRock, Inc., regarding its passive investment holdings. It underscores continued institutional interest in Omnicell, Inc., a company operating in the healthcare technology sector, where such significant institutional ownership is common for established firms.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports a passive ownership stake by a large institutional investor and does not provide performance metrics for direct comparison to industry peers or benchmarks.
• BlackRock's 15.3% stake in Omnicell, Inc. is a substantial position for a single institutional holder, indicating it is a material holding within BlackRock's relevant funds, such as the iShares Core S&P Small-Cap ETF, which is noted to hold over 5% of Omnicell's common stock.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence market perception and liquidity.
• Investors: Offers insight into institutional confidence in Omnicell, Inc., which may be considered by other investors in their investment decisions.

Next Steps

• BlackRock, Inc. will continue to file amendments to its Schedule 13G as required by changes in its beneficial ownership of Omnicell, Inc. or changes in the applicable reporting rules.

Key Dates

Keywords

Omnicell, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment, Shareholding